FrancophonIA/ELRC3.0 huggingface dataset:
English: An evaluation of change over time in score yielded the same trend for EORTC QLQ-C30 and at all visit for FACT-M.
Croatian: Procjena promjene tijekom vremena pokazalo je isti trend za skalu EORTC QLQ-C30 i pri svim posjetima za FACT-M).
English: The risk of haemorrhage may be increased with concomitant use of anticoagulant and antiplatelet therapy.
Croatian: Opasnost od krvarenja može se povećati uz istodobnu primjenu antikoagulantne i antitrombocitne terapije.
English: Genital examinations (for women) and anal examinations are also recommended before the initiation and at the end of your treatment.
Croatian: Također se preporučuju genitalni pregledi (za žene) te analni pregledi prije početka i na kraju liječenja.
English: A decision must be made whether to discontinue breast-feeding or to discontinue Mektovi therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Croatian: Potrebno je odlučiti da li prekinuti liječenje/suzdržati se od liječenja lijekom Mektovi uzimajući u obzir korist dojenja za dijete i korist liječenja za ženu.
English: However, if the missed dose is more than 6 hours late, skip that dose and take your next dose at the usual time.
Croatian: Ali, ako kasnite s propuštenom dozom više od 6 sati, preskočite tu dozu i uzmite sljedeću dozu u uobičajeno vrijeme.
English: What Mektovi looks like and contents of the pack
Croatian: Kako lijek Mektovi izgleda i sadržaj pakiranja
English: Binimetinib is a weak inhibitor of OAT3.
Croatian: Binimetinib je slab inhibitor prijenosnika OAT3.
English: If the adverse reaction that resulted in a dose reduction is under effective management, dose re-escalation to 45 mg twice daily may be considered.
Croatian: Ako je nuspojava koja je dovela do smanjenja doze uspješno zbrinuta, može se razmotriti povećanje doze ponovno na 45 mg dvaput na dan.
English: When Mektovi is used in combination with encorafenib (which targets the changed “BRAF” protein), the combination slows down or stops the growth of your cancer.
Croatian: Kada se lijek Mektovi koristi u kombinaciji s enkorafenibom (koji cilja promijenjeni protein „BRAF”), ova kombinacija usporava ili zaustavlja rast raka.
English: There are insufficient data to evaluate potential differences in the exposure of binimetinib by race or ethnicity.
Croatian: Nema dovoljno podataka za procjenu potencijalnih razlika u izloženosti binimetinibu na temelju rase ili nacionalnosti.
English: Some medicines may affect how Mektovi works, or make it more likely that you will have side effects.
Croatian: Neki lijekovi mogu utjecati na način na koji lijek Mektovi djeluje ili učiniti vjerojatnijim da ćete imati nuspojave.
English: a Hazard ratio based on a stratified Cox proportional hazard model b Log-rank p-value (2-sided)
Croatian: a Omjer hazarda na temelju stratificiranog Coxovog modela proporcionalnog hazarda b log-rang p-vrijednost (dvostrana)
English: Usually, these skin cancers (see also section 2) are confined to a small area and can be removed with surgery and treatment with Mektovi (and encorafenib) can continue without interruption.
Croatian: Te su vrste raka kože (vidjeti također dio 2) uobičajeno ograničene na malu površinu i mogu se ukloniti kirurškim zahvatom, a liječenje lijekom Mektovi (i enkorafenibom) može se nastaviti bez prekida.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Croatian: Bolesnici s rijetkim nasljednim poremećajem nepodnošenja galaktoze, potpunim nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze, ne bi smjeli uzimati ovaj lijek.
English: Patients should be instructed to immediately inform their physicians if new skin lesions develop.
Croatian: Bolesnike se mora savjetovati da svog liječnika odmah obavijeste o pojavi svake nove lezije na koži.
English: Quality of Life (QoL) (cut-off date: 19 May 2016)
Croatian: Procjena kvalitete života (QoL) (datum prestanka prikupljanja podataka: 19. svibnja 2016.)
English: Dose reduction below 30 mg twice daily is not recommended.
Croatian: Ne preporučuje se smanjivanje doze ispod 30 mg dvaput na dan.
English: It is used in adults in combination with another medicine containing encorafenib to treat a type of skin cancer called melanoma when it has
Croatian: Koristi se u odraslih u kombinaciji s drugim lijekom koji sadrži enkorafenib za liječenje vrste raka kože koji se zove melanom
English: Avoid driving or using machines if you have any problems with your vision or have any other side effects that can affect your ability to drive or use machines (see section 4), while taking Mektovi.
Croatian: Izbjegavajte vožnju ili upotrebu strojeva ako imate problema s vidom ili druge nuspojave koje mogu utjecati na vašu sposobnost upravljanja vozilima i strojevima (vidjeti dio 4) dok uzimate lijek Mektovi.
English: The proportion of patients experiencing adverse events and serious adverse events were similar in patients aged <65 years and those aged > 65 years.
Croatian: Udio bolesnika koji su doživjeli štetne događaje i ozbiljne štetne događaje bio je sličan u bolesnika dobi < 65 godina i bolesnika dobi ≥ 65 godina.
English: Blood pressure should be measured at baseline and monitored during treatment, with control of hypertension by standard therapy as appropriate.
Croatian: Potrebno je izmjeriti krvni tlak na početku i nadzirati ga tijekom liječenja, uz kontrolu hipertenzije standardnom terapijom prema potrebi.
English: BRAF mutation testing
Croatian: Testiranje na mutaciju BRAF
English: The potential embryo-foetal effects of binimetinib were evaluated in rats and rabbits.
Croatian: Potencijalni učinci binimetiniba na embrij i fetus procijenjeni su kod štakora i zečeva.
English: Based on a population pharmacokinetic (PK) analysis, the PK of binimetinib were similar in males as compared with females.
Croatian: Na temelju populacijske farmakokinetičke analize (PK), PK binimetiniba bili su slični kod muškaraca i žena.
English: Dose re-escalation to 45 mg twice daily is not recommended if the dose reduction is due to left ventricular dysfunction (LVD) or any Grade 4 toxicity.
Croatian: Ne preporučuje se povećanje doze na 45 mg dvaput na dan ako je doza smanjena uslijed disfunkcije lijeve klijetke (engl. left ventricular dysfunction, LVD) ili bilo koje toksičnosti stupnja 4.
English: The maximum contribution of direct glucuronidation to the clearance of binimetinib was estimated to have been 61.2 %.
Croatian: Maksimalan doprinos izravne glukuronidacije klirensu binimetiniba procijenjen je na 61,2%.
English: Your doctor will examine your eyes for any problems with your sight while you are taking Mektovi.
Croatian: Liječnik će Vam pregledati oči ukoliko imate problema s očima dok uzimate lijek Mektovi.
English: Dose modifications recommendations in case of adverse reactions are presented below and in Tables 1 and 2.
Croatian: Preporuke za prilagođavanje doza u slučaju nuspojava navedene su u Tablicama 1 i 2.
English: Contents of the pack and other information What Mektovi contains
Croatian: Sadržaj pakiranja i druge informacije Što lijek Mektovi sadrži
English: • pain in your legs with or without swelling
Croatian: • bol u nogama sa ili bez oticanja
English: Each film-coated tablet contains 133.5 mg of lactose monohydrate.
Croatian: Jedna filmom obložena tableta sadrži 133,5 mg laktoze hidrata.
English: • feeling like your heart is pounding, racing or beating irregularly
Croatian: • osjećaj kao da vam srce lupa, ubrzano kuca ili kuca nepravilno
English: In repeat-dose toxicity studies, no concern in terms of fertility was raised from pathological examination of reproductive organs in rats and monkeys.
Croatian: U ispitivanjima toksičnosti ponovljene doze nisu utvrđeni problemi vezani uz plodnost pri patološkom ispitivanju reproduktivnih organa kod štakora i majmuna.
English: A minimal risk for photosensitisation was shown in vivo at an oral dose providing 3.8-fold higher exposure than that achieved with the recommended dose in humans.
Croatian: Minimalni rizik za fotosenzibilizaciju pokazao se in vivo pri peroralnoj dozi s 3,8-struko većom izloženosti od one postignute u ljudi pri preporučenim dozama.
English: • a medicine for carcinoma treatment called sorafenib
Croatian: • lijek za liječenje karcinome pod nazivom sorafenib
English: • Uncomplicated deep vein thrombosis (DVT) or pulmonary embolism (PE) ≤ Grade 3
Croatian: • Nekomplicirana duboka venska tromboza (DVT) ili plućna embolija (PE) ≤ stupanj 3
English: Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor, ATC code: L01XE41
Croatian: Farmakoterapijska skupina: antineoplastik, inhibitor protein-kinaze, ATK oznaka: L01XE41 Mehanizam djelovanja
English: Additionally, your doctor needs to check for squamous cell carcinoma on your head, neck, mouth and lymph glands, and you will have CT scans regularly.
Croatian: Dodatno, kako bi isključio prisustvo planocelularnog karcinoma, liječnik će vam pregledati glavu, vrat, usta i limfne žlijezde, a trebate redovito ići i na CT snimanje.
English: Liver metabolism mainly via glucuronidation is the primary route of elimination of binimetinib (see section 5.2).
Croatian: Metabolizam jetre uglavnom putem glukuronidacije primarni je put eliminacije binimetiniba (vidjeti dio 5.2).
English: Age, body weight
Croatian: Posebne populacije Dob, tjelesna težina
English: If you stop taking Mektovi
Croatian: Ako prestanete uzimati lijek Mektovi
English: After repeat twice-daily dosing concomitantly with encorafenib, steady-state conditions for binimetinib were reached within 15 days with no major accumulation.
Croatian: Nakon ponavljanog doziranja dvaput dnevno istodobno s enkorafenibom, stanje dinamičke ravnoteže za binimetinib postignuto je unutar 15 dana bez veće akumulacije.
English: Since binimetinib is highly bound to plasma proteins, haemodialysis is likely to be ineffective in the treatment of overdose with binimetinib.
Croatian: S obzirom da se binimetinib visoko vezuje za proteine plazme, hemodijaliza će vjerojatno biti neučinkovita u liječenju predoziranja binimetinibom.
English: Updated analysis, cut-off date: 07 November 2017
Croatian: Ažurirane analize, datum prestanka prikupljanja podatka: 7. studenoga 2017.
English: • eye problems including glaucoma or increased pressure in your eyes
Croatian: • probleme s očima, uključujući i glaukom ili povećan tlak u očima • probleme s mišićima
English: Binimetinib is 97.2 % bound to human plasma proteins in vitro.
Croatian: Binimetinib se veže za proteine u ljudskoj plazmi (97,2%) in vitro.
English: • blurred vision, loss of vision, or other vision changes (such as coloured dots in your vision)
Croatian: • zamućenje vida, gubitak vida ili druge promjene vida (npr. obojene točkice u vidnom polju)
English: Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.
Croatian: Liječenje je potrebno provoditi sve dok bolesnik od njega ima koristi ili dok ne razvije neprihvatljivu toksičnost.
English: • a medicine used to treat breathing problems, theophylline.
Croatian: • lijek kojim se liječe problemi sa disanjem, teofilin.
English: In addition, simulations to investigate the effect of 400 mg atazanavir (UGT1A1 inhibitor) on the exposure of 45 mg binimetinib predicted similar binimetinib Cmax in the presence or absence of atazanavir.
Croatian: Povrh toga, simulacije za istraživanje učinka 400 mg atazanavira (UGT1A1 inhibitora) na izlaganje dozi od 45 mg binimetiniba predvidjeli su sličan binimetinib Cmax u prisutnosti ili odsustvu atazanavira.
English: Based on its mechanism of action, encorafenib may promote malignancies associated with activation of RAS through mutation or other mechanisms.
Croatian: S obzirom na mehanizam djelovanja, enkorafenib može potpomoći pojavu zloćudne bolesti povezane s aktiviranjem RAS gena putem mutacije ili drugih mehanizama djelovanja.
English: • Symptomatic retinal pigment epithelial detachments (RPED) (Grade 2 or 3)
Croatian: Retinal Pigment Epithelial Detachments, RPED) (stupanj 2 ili 3)
English: Based on a population pharmacokinetic analysis, age or body weight do not have a clinically important effect on the systemic exposure of binimetinib.
Croatian: Na temelju populacijske farmakokinetičke analize utvrđeno je da dob i tjelesna težina nemaju klinički značajan učinak na sistemsku izloženost binimetinibu.
English: Binimetinib has not been evaluated in patients with Gilbert's disease.
Croatian: Binimetinib nije procijenjen u bolesnika s Gilbertovom bolesti.
English: The number of viable foetuses and foetal body weights were reduced and post-implantation loss and resorptions were increased.
Croatian: Broj vijabilnih fetusa i tjelesna težina fetusa smanjeni su, a povećani su postimplantacijski gubitak i resorpcija.
English: In vitro, CYP1A2 and CYP2C19 catalyse the formation of the active metabolite, AR00426032 (M3) by oxidative N-desmethylation.
Croatian: In vitro, CYP1A2 i CYP2C19 kataliziraju stvaranje aktivnih metabolita, AR00426032 (M3) oksidativnom N-demetilacijom.
English: An analysis of time to definitive 10 % deterioration in EORTC QLQ-C30 score provided with similar results.
Croatian: Analiza vremena do jasnog 10% pogoršanja prema rezultatu EORTC QLQ-C30 dala je slične rezultate.
English: In vitro, CYP1A2 and CYP2C19 catalyse the formation of the active metabolite, which represents less than 20 % of the binimetinib exposure clinically.
Croatian: In vitro, CYP1A2 i CYP2C19 kataliziraju stvaranje aktivnih metabolita, što predstavlja manje od 20% kliničkog izlaganja binimetinibu.
English: • some medicines to treat HIV such as indinavir, atazanavir
Croatian: • neki lijekovi za liječenje HIV infekcije, kao što su indinavir, atazanavir
English: Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reaction that may affect their ability to drive and use machines (see sections 4.4 and 4.8).
Croatian: Bolesnicima se mora upozoriti da ne upravljaju vozilom ili rade sa strojevima ako primijete smetnje vida ili bilo kakve nuspojave koje mogu utjecati na njihovu sposobnost upravljanja vozilima ili rada sa strojevima (vidjeti dijelove 4.4 i 4.8).
English: The European Medicines Agency has deferred the obligation to submit the results of studies with binimetinib in one or more subsets of the paediatric population in melanoma (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka binimetinib u jednoj ili više podskupina pedijatrijske populacije s melanomom (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
Croatian: Ako vam je vaš liječnik rekao da ne podnosite neke šećere, obratite se liječniku prije uzimanja ovog lijeka.
English: Visual impairment, including vision blurred and reduced visual acuity, occurred in 21.5 % (59/274) of patients.
Croatian: Poremećaj vida, uključujući i zamućen vid i smanjenu vidnu oštrinu, javili su se u 21,5% (59/274) bolesnika.
English: Patients were permitted to receive prior adjuvant therapy and one prior line of immunotherapy for unresectable locally advanced or metastatic disease.
Croatian: Bolesnicima je bilo dozvoljeno prethodno primiti jednu adjuvantnu kemoterapiju i jednu liniju imunoterapije za neoperabilnu lokalno uznapredovalu ili metastatsku bolest.
English: Binimetinib should be withheld for up to 2 weeks and ophthalmic monitoring should be repeated including visual acuity assessment.
Croatian: Treba prekinuti binimetinib u razdoblju do 2 tjedna i ponoviti oftalmološko praćenje uključujući procjenu vidne oštrine.
English: Binimetinib has phototoxic potential in vitro.
Croatian: Binimetinib pokazuje fototoksični potencijal in vitro.
English: Inhibition of P-gp or BCRP is unlikely to result in a clinically important increase in binimetinib concentrations as binimetinib exhibits moderate to high passive permeability.
Croatian: Malo je vjerojatno da inhibicija P-gp-a ili BCRP-a dovodi do klinički značajnog povećanja u koncentracijama binimetiniba, budući da binimetinib pokazuje umjerenu do visoku pasivnu permeabilnost.
English: As Mektovi is to be used in combination with encorafenib, read the encorafenib leaflet carefully as well as this leaflet.
Croatian: Budući da se lijek Mektovi koristi u kombinaciji s enkorafenibom, pažljivo pročitajte uputu za enkorafenib, kao i ovu uputu.
English: The median time to first occurrence of LVD (any grade) was 4.4 months (range 0.03 to 21.3 months) in patients who developed an LVEF below 50 %.
Croatian: Medijan vremena do prvog pojavljivanja LVD-a (za sve stupnjeve) iznosio je 4,4 mjeseca (u rasponu od 0,03 do 21,3 mjeseci) u bolesnika koji su razvili LVEF ispod 50%.
English: Therefore, the extent of drug interactions mediated by UGT1A1 is minimal, and unlikely clinically relevant; however, as this has not been evaluated in a formal clinical study, UGT1A1 inducers or inhibitors should be administered with caution.
Croatian: Stoga, razmjer interakcije lijekova posredovanih s UGT1A1 minimalan je i nije vjerojatno da će biti klinički relevantan; međutim, budući da to nije procijenjeno u službenom kliničkom ispitivanju, UGT1A1 induktore ili inhibitore potrebno je primjenjivati s oprezom.
English: Gastrointestinal disorders were typically managed with standard therapy.
Croatian: Poremećaji probavnog sustava bili su uobičajeno liječeni standardnom terapijom.
English: It is unknown whether binimetinib or its metabolite are excreted in human milk.
Croatian: Nije poznato izlučuju li se binimetinib ili njegovi metaboliti u majčino mlijeko.
English: Other medicines and Mektovi
Croatian: Drugi lijekovi i lijek Mektovi
English: Hypertension, or worsening of pre-existing hypertension, can occur with the use of binimetinib.
Croatian: Hipertenzija ili pogoršanje postojeće hipertenzije može se pojaviti prilikom upotrebe binimetiniba.
English: For patients receiving 45 mg binimetinib twice daily, the recommended reduced dose of binimetinib is 30 mg twice daily.
Croatian: Za bolesnike koji primaju 45 mg binimetiniba dvaput na dan: preporučena smanjena doza binimetiniba je 30 mg dvaput na dan.
English: How to take Mektovi How much to take
Croatian: Kako uzimati lijek Mektovi Koliko lijeka uzeti
English: Before taking binimetinib in combination with encorafenib, patients must have BRAF V600 mutation confirmed by validated test.
Croatian: Prije uzimanja binimetiniba u kombinaciji s enkorafenibom, bolesnici moraju imati mutaciju BRAF V600 potvrđenu validiranim testom.
English: PFS as assessed by investigators (investigator assessment) was a supportive analysis.
Croatian: Preživljenje bez progresije (PFS) ocijenjeno od strane ispitivača bilo je potporna analiza djelotvornosti.
English: • Lung or breathing problems: This medicine may cause lung or breathing problems including inflammation of the lungs (pneumonitis or interstitial lung disease); signs and symptoms can include: cough, shortness of breath or fatigue.
Croatian: • Problemi s plućima ili disanjem: ovaj lijek može prouzročiti probleme s plućima ili disanjem, uključujući upalu pluća (pneumonitis ili intersticijska bolest pluća); znakovi i simptomi mogu uključivati sljedeće: kašalj, nedostatak zraka ili umor.
English: Besides the serious side effects mentioned above, people taking Mektovi and encorafenib together may also get the following side effects.
Croatian: Osim gore spomenutih ozbiljnih nuspojava, osobe koje uzimaju zajedno lijekove Mektovi i enkorafenib mogu iskusiti i sljedeće nuspojave.
English: • a cool, pale arm or leg
Croatian: • hladne, blijede ruke ili noge
English: The most common adverse events reported with a higher incidence in patients aged ≥ 65 years compared to patients aged < 65 years included diarrhoea, pruritus, GGT and blood phosphatase alkaline elevation.
Croatian: Najčešće zabilježeni štetni događaji koji su imali veću incidenciju u bolesnika dobi ≥ 65 godina u usporedbi s bolesnicima dobi < 65 godina uključivali su proljev, pruritus, porast GGT i alkalne fosfataze u krvi.
English: A definitive 10% deterioration in FACT-M and in EORTC QLQ-C30 was significantly delayed in patients treated with Combo 450 relative to other treatments.
Croatian: Jasno pogoršanje od 10% prema FACT-M i EORTC QLQ-C30 značajno je odgođeno u bolesnika liječenih s kombiniranom terapijom 450 u usporedbi s drugim vrstama liječenja.
English: In clinical study sub-analysis, however, there was no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.
Croatian: Međutim, u podanalizi kliničkog ispitivanja nije primijećen jasan odnos između izlaganja binimetinibu i statusa UGT1A1 mutacije.
English: Most patients had metastatic disease (95 %) and were Stage IVM1c (64 %); 27 % of patients had elevated baseline serum lactate dehydrogenase (LDH), and 45% of patients had at least 3 organs with tumour involvement at baseline and 3.5 % had brain metastases.
Croatian: Većina bolesnika imala je metastatsku bolest (95%) i bila u stadiju IVM1c (64%); 27% bolesnika imalo je povišenu početnu vrijednost serumske laktat dehidrogenaze (LDH), 45% bolesnika je na početku imalo najmanje 3 organa zahvaćenih tumorom, a 3,5% je već imalo metastaze na mozgu.
English: • sudden shortness of breath or trouble breathing
Croatian: • iznenadan nedostatak zraka ili poteškoće s disanjem
English: Elderly patients No dose adjustment is required for patients aged 65 years and older (see section 5.2).
Croatian: Za bolesnike u dobi od 65 godina ili starijih nije potrebna prilagodba doze (vidjeti dio 5.2).
English: The patient should be advised to maintain an adequate fluid intake during treatment.
Croatian: Bolesnika je potrebno savjetovati o potrebnom odgovarajućem unosu tekućine tijekom liječenja.
English: In case of severe hypertension, temporary interruption of binimetinib is recommended until hypertension is controlled (see Table 2 in section 4.2).
Croatian: U slučaju teške hipertenzije preporučuje se privremen prekid liječenja binimetinibom dok se hipertenzija ne stavi pod kontrolu (vidjeti Tablicu 2 u dijelu 4.2).
English: • Grade 4 PE
Croatian: • Stupanj 4 PE
English: Effect of binimetinib on CYP substrates Binimetinib is a weak reversible inhibitor of CYP1A2 and CYP2C9.
Croatian: Učinak binimetiniba na CYP supstrate Binimetinib je slab reverzibilni inhibitor za CYP1A2 i CYP2C9.
English: Binimetinib should be permanently discontinued with the occurrence of RVO (see Table 1 in section 4.2).
Croatian: Binimetinib treba trajno obustaviti u slučaju pojave RVO-a (vidjeti Tablicu 1 u dijelu 4.2).
English: If treatment-related toxicities occur when binimetinib is used in combination with encorafenib, then both treatments should be simultaneously dose reduced, interrupted or discontinued.
Croatian: Ako se pojave toksičnosti povezane s liječenjem kada se binimetinib primjenjuje u kombinaciji s enkorafenibom, u obje je terapije istovremeno potrebno smanjiti dozu, privremeno ih prekinuti ili trajno obustaviti.
English: These data indicate that there is minimal risk for phototoxicity with binimetinib at therapeutic doses in patients.
Croatian: Ovi podaci sugeriraju da binimetinib nosi minimalan rizik fototoksičnosti pri terapijskim dozama kod bolesnika.
English: Mektovi is available in packs of 84 tablets (7 blisters of 12 tablets each) or 168 tablets (14 blisters of 12 tablets each).
Croatian: Lijek Mektovi 75 mg dostupan je u pakiranjima od 84 tablete (7 blistera od po 12 tableta) ili 168 tablete (14 blistera od po 12 tablete).
English: Dermatologic reactions Dermatologic reactions may occur when binimetinib is used in combination with encorafenib.
Croatian: Dermatološke reakcije Dermatološke se reakcije mogu javiti kada se binimetinib primjenjuje u kombinaciji s enkorafenibom.
English: If you forget to take Mektovi
Croatian: Ako ste zaboravili uzeti lijek Mektovi